InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
1
T+90 hit rate
25%
T+90 mean return
-17.3%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Peterson Amy C., Vice-Président Exécutif du Développement. Director active across 2 companies, notably CytomX Therapeutics, Inc.. In total, 12 filings have been recorded. Split: 0 buy · 1 sell. Total volume traded: €8k. Activity tracked since 31 May 2021. The latest transaction was filed on 15 May 2025 (Retenue fiscale). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations12 total
8,303 shares@ US$44.6526.8% of flowCommon StockSEC:0000939767-25-000076:0
159,383 shares0Common StockSEC:0000939767-25-000055:0
52,192 shares0Common StockSEC:0000939767-25-000040:0
27,224 shares@ US$35.0573.2% of flowCommon StockSEC:0000939767-24-000158:0
82,121 shares0Common StockSEC:0000939767-24-000035:0
240,000 shares0Common StockSEC:0000939767-23-000098:0
4,257 shares@ US$1.97919.4% of flowCommon StockSEC:0001140361-23-012614:0
20,000 shares0Common StockSEC:0001567619-22-014301:0
40,000 shares0Common StockSEC:0001567619-22-002525:0
40,000 shares0Common StockSEC:0001567619-22-002525
3,320 shares@ US$6.0860.0023% mcap50.0% of flowCommon StockSEC:0001567619-21-011806:0
3,320 shares@ US$6.08640.3% of flowCommon StockSEC:0001567619-21-011806
12 of 12 declarations
About Peterson Amy C.
Amy C. Peterson is the Executive Vice President of Development at CytomX Therapeutics, Inc. In this role, she oversees the company's strategic development initiatives, aiming to innovate and improve medical treatments. Her expertise is essential for the success of the company's projects.
